**Name of Journal:** *World Journal of Radiology*

**Manuscript NO:** 63495

**Manuscript Type:** MINIREVIEWS

**Thoracic imaging outcomes in COVID-19 survivors**

Alqahtani JS *et al*. Imaging outcomes in COVID-19 survivors

Jaber S Alqahtani, Saeed M Alghamdi, Abdulelah M Aldhahir, Malik Althobiani, Reynie Purnama Raya, Tope Oyelade

**Jaber S Alqahtani,** Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam 3431, Saudi Arabia

**Jaber S Alqahtani, Malik Althobiani,** Department of Respiratory Medicine, Division of Medicine, University College London, London NW3 2PF, United Kingdom

**Saeed M Alghamdi,** Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 21990, Saudi Arabia

**Abdulelah M Aldhahir,** Respiratory Care Department, Faculty of Applied Medical Sciences, Jazan University, Jazan 4514, Saudi Arabia

**Malik Althobiani,** Department of Respiratory Therapy, King Abdulaziz University, Jeddah 21589, Saudi Arabia

**Reynie Purnama Raya,** Faculty of Science, Universitas ‘Aisyiyah Bandung, Bandung 40264, Indonesia

**Reynie Purnama Raya,** Institute for Global Health, Division of Medicine, University College London, London NW3 2PF, United Kingdom

**Tope Oyelade,** Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, United Kingdom

**Author** **contributions:** Alqahtani JS contributed conceptualization, data collection, formal analysis, project administration, wrote original draft, reviewed and edited the manuscript; Alghamdi SM, Aldhahir AM and Oyelade T contributed data collection, formal analysis, reviewed and edited the manuscript; Althobiani M and Raya RP reviewed and edited the manuscript.

**Corresponding author: Jaber S Alqahtani, MSc, Academic Research, Lecturer,** Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dhahran, Dammam 3431, Saudi Arabia. Alqahtani-Jaber@hotmail.com

**Received:** January 28, 2021

**Revised:** May 13, 2021

**Accepted:** June 2, 2021

**Published online:**

**Abstract**

The coronavirus disease 2019 (COVID-19) pandemic presents a significant global public health challenge. One in five individuals with COVID-19 presents with symptoms that last for weeks after hospital discharge, a condition termed "long COVID". Thus, efficient follow-up of patients is needed to assess the resolution of lung pathologies and systemic involvement. Thoracic imaging is multimodal and involves using different forms of waves to produce images of the organs within the thorax. In general, it includes chest X-ray, computed tomography, lung ultrasound and magnetic resonance imaging techniques. Such modalities have been useful in the diagnosis and prognosis of COVID-19. These tools have also allowed for the follow-up and assessment of long COVID. This review provides insights on the effectiveness of thoracic imaging techniques in the follow-up of COVID-19 survivors who had long COVID.

**Key Words:** Long COVID; COVID-19; SARS-CoV-2; Thoracic imaging; Computed tomography; Survivors; Chest X-ray; Lung ultrasound

Alqahtani JS, Alghamdi SM, Aldhahir AM, Althobiani M, Raya RP, Oyelade T. Thoracic imaging outcomes in COVID-19 survivors. *World J Radiol* 2021; In press

**Core Tip:** The coronavirus disease 2019 (COVID-19) pandemic presents a significant global public health challenge. One in five individuals with COVID-19 presents with symptoms that last for weeks after hospital discharge, a condition termed "long COVID". This review provides insights on findings of thoracic imaging techniques in the follow-up of COVID-19 survivors who had long COVID.

**INTRODUCTION**

The global coronavirus disease 2019 (COVID-19) pandemic continues to cause significant morbidity and mortality worldwide[1-3]. To date, the focus of research communication has been on the management of acute respiratory complications, particularly in critically ill patients[4,5]. However, since June 2020 increased attention has been paid to the experiences of COVID-19 survivors whose symptoms continue for four or more weeks[6]. According to the Office for National Statistics, one in five individuals has symptoms that continue after five weeks, and one in ten has symptoms for 12 wk or longer after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[7]. This is called “long COVID” and is defined as a condition in which infected people do not fully recover for several weeks or months after signs indicative of SARS-CoV-2 infection[8]. Studies on long COVID exploring the underlying pathology and sequelae, as well as rehabilitation for patients, are increasing. Data shows that many patients with long COVID develop serious clinical complications[9-11] and require follow-up to confirm full resolution of symptoms.

An imaging test refers to the generation of image results that are clinically relevant for clinical diagnosis, guiding management, triage, and therapy. Chest radiography, computed tomography (CT), lung ultrasound (LUS), and magnetic resonance imaging (MRI) provide additional clinical insights on COVID-19 patients to better understand long COVID complications. Early and accurate diagnosis, as well as guided management of COVID-19-related complications, is important[12]. Further, because of the tendency toward extended sequelae of COVID-19 symptoms, some of which include multi-organ involvement, there is an increasing need to develop follow-up strategies to prevent further deterioration of patients. Therefore, this review provides an update on the effectiveness of thoracic imaging techniques in the follow-up of COVID-19 survivors who suffer from long COVID.

**The use of thoracic imaging in COVID-19 patients**

Using diagnostic thoracic imaging techniques on patients diagnosed with COVID-19 can sometimes be challenging due to the strict infection control measures that are required to prevent or reduce the spread of infection to healthcare providers and other patients[13]. However, various imaging modalities have been used due to the value of thoracic imaging in detection and monitoring of disease progression. Generally, chest radiography and CT of the chest are used with COVID-19, while the use of MRI and LUS is limited in the literature[14].

In the early stages of COVID-19 infection, chest radiography is insensitive especially in mild cases[15], whereas CT is more sensitive for early parenchymal lung disease, disease progression, and alternative diagnoses, including acute heart failure[16]. Nevertheless, concerning the importance of chest radiography or CT for diagnosing viral pneumonia, experiences and decisions vary widely based on cultural standards and public health recommendations[17]. This is exemplified in China where patients are encouraged to present themselves early in the course of their disease when chest radiography has limited clinical value. CT has therefore proved a more efficient tool in detecting COVID-19 and guiding public health measures such as self-isolation[16]. In contrast, patients in the US have been instructed to stay at home until they suffer severe symptoms and so, as expected, a chest radiograph is generally abnormal at the time of presentation. In some countries, chest radiography is preferred in certain groups of patients because of portability; therefore, imaging can be performed in an infected patient’s isolation room, thus reducing the risk of SARS-CoV-2 transmission that may result from in-hospital transportation[17]. Although chest radiography can be beneficial for evaluating disease progress and alternative diagnoses, many hospitals rely on CT scan findings when clinical management decisions are needed, such as discharge from hospital or the need for intensive care unit[18]. Generally, the choice of thoracic imaging will depend on available equipment (chest radiography, CT, MRI or LUS), expertise, and the judgment of the healthcare staff at the points of care, with the final decision based on appropriate and reasonable assessment of related risks.

**Chest radiography in COVID-19 survivors**

Chest radiography, also referred to as chest X-ray (CXR), involves using short wavelength electromagnetic radiation to produce images of the chest's internal organs. With moderate ease of use and interpretation and low side effects, CXR remains one of the oldest and most used non-invasive chest imaging techniques[19]. However, in the context of COVID-19, the use of CXR has been reported to vary in importance and usefulness in both diagnosis and prognostication of disease course. Common CXR findings that have been described in COVID-19 patients are pulmonary lesions associated with inflammatory injuries, ground-glass opacity (GGO), linear opacity consolidation, crazy-paving pattern and vacuolar sign[20].

GGO remains the major structural change indicative of COVID-19 infection, with a majority of patients developing bilateral CXR findings of this nature[21,22]. A combination of GGO and consolidation of the lung image usually occurs in the periphery of the lung[23] and is scored from 0-4 based on the percentage of the lung affected[24]. In a study by Wong *et al*[15], the sensitivity of baseline CXRs in the diagnosis of COVID-19 was 62%, with 9% of patients showing abnormal CT findings before reverse transcription polymerase chain reaction (RT-PCR) confirmation of SARS-CoV-2 infection. A significant majority of patients with COVID-19 infection show CXR abnormalities indicative of damage to the lung tissue, which is attributable to systemic inflammatory response syndrome[22,25].

In most patients who survive severe COVID-19, there is a significant tendency to develop fibrotic lung tissue after recovery. However, while CRX is promising in diagnosing COVID-19, its use as a marker for pulmonary tissue recovery in patients with long COVID-19 remains unclear. For instance, in a study assessing 119 COVID-19 patients, D’cruz *et al*[26] found that follow-up CRX did not correlate with abnormal CT findings or prolonged functional disability in infected patients, while another study involving 134 patients concluded that CXR findings were an independent risk factor for poorer prognosis in COVID-19 patients[20]. Liao *et al*[22], in another study of 172 COVID-19 survivors, showed that 86% of patients had abnormal CT findings three months after discharge. In this study, change in CXR findings was associated with recovery duration, and abnormal lung findings were reported to correlate significantly with severity of COVID-19. Generally, the effectiveness of CXR as a prognostic marker or in tracking lung tissue regeneration in patients with long COVID remains uncertain.

**CT in COVID-19 survivors**

CT scans have been extensively used in the diagnosis of COVID-19. In a series of 51 patients, the sensitivity of CT scan in detecting SARS-CoV-2 infection was reported to be higher (98%) compared to RT-PCR (71%)[27,28]. In another study involving 167 patients considered at high risk for SARS-CoV-2 infection, chest CT scan confirming viral pneumonia correlated significantly with positive RT-PCR results[29]. Generally, chest CT findings of lung tissue pathology are similar to those of CXR scans in COVID-19 and are scored based on bilateral lung involvement, including GGO, consolidation, vacuolar sign, linear opacity and crazy-paving pattern[30,31]. However, while the sensitivity of CT is high in detecting lung tissue pathology associated with pneumonic infections, the specificity for SARS-CoV-2 infection is relatively low (25%-56%)[31].

Because of its sensitivity, the first point of call and the reference technique for chest imaging has been CT. Although CT is expensive, less portable and available, and requires well-trained and experienced radiographers for standard operation and interpretation of findings[32], it has been extensively used in the prognosis and follow-up of COVID-19 patients. In a study involving 55 COVID-19 survivors followed up for three months after discharge, abnormal CT findings were detected in 71% of patients[33]. Another study in which final CT scans were obtained from 70 COVID-19 survivors at discharge showed unresolved lung tissue pathology in 94% of the patients, mainly in the form of residual GGO (60%)[34]. Tabatabaei *et al*[35] studied 52 patients who had recovered from COVID-19 and reported residual CT abnormalities in 42% of the survivors. These findings showed significant correlation with disease severity. Generally, CT is a useful and more sensitive tool in the follow-up of patients recovered from COVID-19. It may be helpful in the assessment of treatment effects.

**LUS in COVID-19 survivors**

LUS provides a faster, safer and more sensitive assessment of lung tissue pathology compared to radiation-based CXR and has been extensively used in the monitoring of patients with COVID-19. LUS is also relatively more accessible because of the inherent portability and bedside availability, making it a technique of choice where timely assessment of lung complications is needed, especially in COVID-19 patients with severe or unstable health conditions[36]. Further, the ability to delineate alterations in superficial lung tissue through the air and tissue ratio (using A- and B-lines) makes LUS unique and more sensitive in characterizing the nature, topography, and size of lung tissue lesions[37,38]. In general, irregular thickening of the pleural line, heterogeneous B-lines and consolidations, pleural effusions, and recovery-phase A-lines in the lung image have been detected in COVID-19 patients using ultrasonography[39-41]. LUS has been reported to correlate strongly with systemic inflammation and severity of COVID-19, although not with survival[42].

In the follow-up of COVID-19 survivors with long-persisting symptoms, LUS findings have shown promising outcomes. In a case series of long COVID patients by Tung-Chen *et al*[43], LUS findings correlated with chest CT and accurately assessed the resolution of residual lung tissue abnormalities. LUS findings, specifically the frequency of B-lines, which measures the thickening of pleural lines, were also reported to correlate with the duration of COVID-19 symptoms in patients[44]. Further, LUS was successfully used in the assessment of the progression of COVID-19 in a 35-year-old survivor for up to three weeks in a home setting[45]. These highlights both the sensitivity and availability of LUS for the assessment of both short- and long-term effects of SARS-CoV-2 infection.

**MRI in COVID-19 survivors**

MRI was first introduced in the United Kingdom in 1980, and since that time, it has become widely used in clinical practice[46,47]. It is extremely effective, particularly in the diagnosis of patients without exposing them to dangerous ionising radiation[48]. Angiotensin-converting enzyme 2 (ACE2) is the path for SARS-CoV-2 to attack thoracic organs, including lung and cardiac systems. MRI has been used regularly to assess cardiac involvement in patients who have recovered from COVID-19[11,49]. Huang *et al*[49] conducted a study on patients who reported cardiac symptoms during their hospitalization due to COVID-19 to assess whether there was continued cardiac involvement after the patients’ recovery from COVID-19. This study found that 58% of the recovered patients had abnormal MRI findings, including myocardial oedema (54%) and late gadolinium enhancement (31%). Further, fibrosis and compromised right ventricle function have also been found in patients who have recovered from COVID-19. In another study conducted by Puntmann *et al*[11], independent of pre-existing comorbidities, severity and overall course of the acute illness, cardiac involvement was reported in 78% of patients and around 60% had ongoing myocardial inflammation. The abnormal findings included elevated myocardial native T1 and myocardial native T2 and pericardial enhancement. Cardiac involvement in patients recovered from COVID-19 is common and has the potential to affect the overall prognosis. Although rarely used, MRI is effective in detecting cardiac involvement in patients and provides a holistic diagnostic assessment of residual symptoms in COVID-19 survivors. Further studies are essential to explore the long-term cardiopulmonary burden of long COVID.

In summary, Table 1 shows the major findings of thoracic imaging tools in COVID-19 survivors.

**Key Points**

(1) COVID-19 survivors sometimes develop long-term sequelae, generally termed “long COVID”, which can be assessed by different imaging tests; (2) Various imaging modes have been used as diagnostic, prognostic, and follow-up tools in COVID-19. However, sensitivity and specificity, as well as modes and ease of use, vary; (3) The effectiveness of CRX as a prognostic marker or in tracking lung tissue regeneration in patients with long COVID remains uncertain; (4) CT is a relatively more sensitive tool in the follow up of COVID-19 survivors and could be used for the assessment of treatment effects; (5) LUS is sensitive and relatively more portable than radiology-based imaging tools, allowing for use in out-of-hospital settings, and it may be the best tool for the follow-up of COVID-19 survivors; and (6) Although rarely used, MRI is effective in detecting cardiac involvement in patients and provides a holistic diagnostic assessment of residual symptoms in COVID-19 survivors.

**CONCLUSION**

COVID-19 survivors, especially those with a severe clinical course, have residual lung tissue abnormalities and suffer extensive sequelae, currently termed “long COVID”. Fibrotic lung tissue from systemic inflammatory response to SARS-CoV-2 infection is characteristic of severe COVID-19 and can be picked up in follow-up scans. Various imaging techniques have been extensively used for the follow-up of long COVID, including CXR, CT, LUS and MRI with varying efficiency. However, CT remains the most commonly used because of its sensitivity, while LUS is favoured because of its accessibility and portability.

**REFERENCES**

1 **Alqahtani JS**, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, Quaderi S, Mandal S, Hurst JR. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. *PLoS One* 2020; **15**: e0233147 [PMID: 32392262 DOI: 10.1371/journal.pone.0233147]

2 **Shi S**, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol* 2020; **5**: 802-810 [PMID: 32211816 DOI: 10.1001/jamacardio.2020.0950]

3 **Richardson S**, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020; **323**: 2052-2059 [PMID: 32320003 DOI: 10.1001/jama.2020.6775]

4 **Alhazzani W**, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med* 2020; **46**: 854-887 [PMID: 32222812 DOI: 10.1007/s00134-020-06022-5]

5 **Alqahtani JS**, Mendes RG, Aldhahir A, Rowley D, AlAhmari MD, Ntoumenopoulos G, Alghamdi SM, Sreedharan JK, Aldabayan YS, Oyelade T, Alrajeh A, Olivieri C, AlQuaimi M, Sullivan J, Almeshari MA, Esquinas A. Global Current Practices of Ventilatory Support Management in COVID-19 Patients: An International Survey. *J Multidiscip Healthc* 2020; **13**: 1635-1648 [PMID: 33239884 DOI: 10.2147/JMDH.S279031]

6 **Shah W**, Heightman M, O'Brien S. UK guidelines for managing long-term effects of COVID-19. *Lancet* 2021; **397**: 1706 [PMID: 33965081 DOI: 10.1016/S0140-6736(21)00847-3]

7 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]

8 **Nabavi N**. Long covid: How to define it and how to manage it. *BMJ* 2020; **370**: m3489 [PMID: 32895219 DOI: 10.1136/bmj.m3489]

9 **Greenhalgh T**, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ* 2020; **370**: m3026 [PMID: 32784198 DOI: 10.1136/bmj.m3026]

10 **Mandal S**, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, Lipman MCI, Naidu SB, Nair A, Porter JC, Tomlinson GS, Hurst JR; ARC Study Group. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. *Thorax* 2020 [PMID: 33172844 DOI: 10.1136/thoraxjnl-2020-215818]

11 **Puntmann VO**, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020; **5**: 1265-1273 [PMID: 32730619 DOI: 10.1001/jamacardio.2020.3557]

12 **Gorna R**, MacDermott N, Rayner C, O'Hara M, Evans S, Agyen L, Nutland W, Rogers N, Hastie C. Long COVID guidelines need to reflect lived experience. *Lancet* 2021; **397**: 455-457 [PMID: 33357467 DOI: 10.1016/S0140-6736(20)32705-7]

13 **Mossa-Basha M**, Meltzer CC, Kim DC, Tuite MJ, Kolli KP, Tan BS. Radiology Department Preparedness for COVID-19: *Radiology* Scientific Expert Review Panel. *Radiology* 2020; **296**: E106-E112 [PMID: 32175814 DOI: 10.1148/radiol.2020200988]

14 **Soldati G**, Smargiassi A, Inchingolo R, Buonsenso D, Perrone T, Briganti DF, Perlini S, Torri E, Mariani A, Mossolani EE, Tursi F, Mento F, Demi L. Is There a Role for Lung Ultrasound During the COVID-19 Pandemic? *J Ultrasound Med* 2020; **39**: 1459-1462 [PMID: 32198775 DOI: 10.1002/jum.15284]

15 **Wong HYF**, Lam HYS, Fong AH, Leung ST, Chin TW, Lo CSY, Lui MM, Lee JCY, Chiu KW, Chung TW, Lee EYP, Wan EYF, Hung IFN, Lam TPW, Kuo MD, Ng MY. Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. *Radiology* 2020; **296**: E72-E78 [PMID: 32216717 DOI: 10.1148/radiol.2020201160]

16 **Ai T**, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology* 2020; **296**: E32-E40 [PMID: 32101510 DOI: 10.1148/radiol.2020200642]

17 **Rubin GD**, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, Inoue Y, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. *Chest* 2020; **158**: 106-116 [PMID: 32275978 DOI: 10.1016/j.chest.2020.04.003]

18 **Orsi MA**, Oliva AG, Cellina M. Radiology Department Preparedness for COVID-19: Facing an Unexpected Outbreak of the Disease. *Radiology* 2020; **295**: E8 [PMID: 32228364 DOI: 10.1148/radiol.2020201214]

19 **Pezzotti W**. Chest X-ray interpretation: not just black and white. *Nursing* 2014; **44**: 40-7; quiz 47-8 [PMID: 24281317 DOI: 10.1097/01.NURSE.0000438704.82227.44]

20 **Zhou S**, Chen C, Hu Y, Lv W, Ai T, Xia L. Chest CT imaging features and severity scores as biomarkers for prognostic prediction in patients with COVID-19. *Ann Transl Med* 2020; **8**: 1449 [PMID: 33313194 DOI: 10.21037/atm-20-3421]

21 **Cleverley J**, Piper J, Jones MM. The role of chest radiography in confirming covid-19 pneumonia. *BMJ* 2020; **370**: m2426 [PMID: 32675083 DOI: 10.1136/bmj.m2426]

22 **Liao X**, Wang Y, He Z, Yun Y, Hu M, Ma Z, Huang L, Cai Q, Xu L, Hao Y, Liu L. Three-month pulmonary function and radiological outcomes in COVID-19 survivors: a longitudinal patient cohort study. *Open Forum Infect Dis* 2020: ofaa540 [DOI: 10.1093/ofid/ofaa540]

23 **Jacobi A**, Chung M, Bernheim A, Eber C. Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review. *Clin Imaging* 2020; **64**: 35-42 [PMID: 32302927 DOI: 10.1016/j.clinimag.2020.04.001]

24 **Warren MA**, Zhao Z, Koyama T, Bastarache JA, Shaver CM, Semler MW, Rice TW, Matthay MA, Calfee CS, Ware LB. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. *Thorax* 2018; **73**: 840-846 [PMID: 29903755 DOI: 10.1136/thoraxjnl-2017-211280]

25 **Sun D**, Li X, Guo D, Wu L, Chen T, Fang Z, Chen L, Zeng W, Yang R. CT Quantitative Analysis and Its Relationship with Clinical Features for Assessing the Severity of Patients with COVID-19. *Korean J Radiol* 2020; **21**: 859-868 [PMID: 32524786 DOI: 10.3348/kjr.2020.0293]

26 **D'Cruz RF**, Waller MD, Perrin F, Periselneris J, Norton S, Smith LJ, Patrick T, Walder D, Heitmann A, Lee K, Madula R, McNulty W, Macedo P, Lyall R, Warwick G, Galloway JB, Birring SS, Patel A, Patel I, Jolley CJ. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. *ERJ Open Res* 2021; **7** [PMID: 33575312 DOI: 10.1183/23120541.00655-2020]

27 **Fang Y**, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. *Radiology* 2020; **296**: E115-E117 [PMID: 32073353 DOI: 10.1148/radiol.2020200432]

28 **Kim H**, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis. *Radiology* 2020; **296**: E145-E155 [PMID: 32301646 DOI: 10.1148/radiol.2020201343]

29 **Xie X**, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RT-PCR Testing. *Radiology* 2020; **296**: E41-E45 [PMID: 32049601 DOI: 10.1148/radiol.2020200343]

30 **Zhao W**, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. *AJR Am J Roentgenol* 2020; **214**: 1072-1077 [PMID: 32125873 DOI: 10.2214/AJR.20.22976]

31 **Jalaber C**, Lapotre T, Morcet-Delattre T, Ribet F, Jouneau S, Lederlin M. Chest CT in COVID-19 pneumonia: A review of current knowledge. *Diagn Interv Imaging* 2020; **101**: 431-437 [PMID: 32571748 DOI: 10.1016/j.diii.2020.06.001]

32 **Fred HL**. Drawbacks and limitations of computed tomography: views from a medical educator. *Tex Heart Inst J* 2004; **31**: 345-348 [PMID: 15745283]

33 **Zhao YM**, Shang YM, Song WB, Li QQ, Xie H, Xu QF, Jia JL, Li LM, Mao HL, Zhou XM, Luo H, Gao YF, Xu AG. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. *EClinicalMedicine* 2020; **25**: 100463 [PMID: 32838236 DOI: 10.1016/j.eclinm.2020.100463]

34 **Wang Y**, Dong C, Hu Y, Li C, Ren Q, Zhang X, Shi H, Zhou M. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology* 2020; **296**: E55-E64 [PMID: 32191587 DOI: 10.1148/radiol.2020200843]

35 **Tabatabaei SMH**, Rajebi H, Moghaddas F, Ghasemiadl M, Talari H. Chest CT in COVID-19 pneumonia: what are the findings in mid-term follow-up? *Emerg Radiol* 2020; **27**: 711-719 [PMID: 33165674 DOI: 10.1007/s10140-020-01869-z]

36 **Wang B**, Zhang L, Zhang D, Yuan H, Wu C, Zhang Y, He L, Wang R, Wang J, Xie M. Bedside ultrasound in assessment of 510 severe and critical patients with COVID-19 pneumonia in Wuhan, China. *AUDT* 2020; **4**: 60-66 [DOI: 10.37015/AUDT.2020.200018]

37 **Soldati G**, Smargiassi A, Inchingolo R, Buonsenso D, Perrone T, Briganti DF, Perlini S, Torri E, Mariani A, Mossolani EE, Tursi F, Mento F, Demi L. Proposal for International Standardization of the Use of Lung Ultrasound for Patients With COVID-19: A Simple, Quantitative, Reproducible Method. *J Ultrasound Med* 2020; **39**: 1413-1419 [PMID: 32227492 DOI: 10.1002/jum.15285]

38 **Alqahtani JS**, Oyelade T, Sreedharan J, Aldhahir AM, Alghamdi SM, Alrajeh AM, Alqahtani AS, Alsulayyim A, Aldabayan YS, Alobaidi NY, AlAhmari MD. Diagnostic and clinical values of non-cardiac ultrasound in COPD: A systematic review. *BMJ Open Respir Res* 2020; **7** [PMID: 32978244 DOI: 10.1136/bmjresp-2020-000717]

39 **Peng QY**, Wang XT, Zhang LN; Chinese Critical Care Ultrasound Study Group (CCUSG). Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic. *Intensive Care Med* 2020; **46**: 849-850 [PMID: 32166346 DOI: 10.1007/s00134-020-05996-6]

40 **Denault AY**, Delisle S, Canty D, Royse A, Royse C, Serra XC, Gebhard CE, Couture ÉJ, Girard M, Cavayas YA, Peschanski N, Langevin S, Ouellet P. A proposed lung ultrasound and phenotypic algorithm for the care of COVID-19 patients with acute respiratory failure. *Can J Anaesth* 2020; **67**: 1393-1404 [PMID: 32440906 DOI: 10.1007/s12630-020-01704-6]

41 **Gil-Rodrigo A**, Llorens P, Martínez-Buendía C, Luque-Hernández MJ, Espinosa B, Ramos-Rincón JM. Diagnostic yield of point-of-care ultrasound imaging of the lung in patients with COVID-19. *Emergencias* 2020; **32**: 340-344 [PMID: 33006834]

42 **Rojatti M**, Regli IB, Zanforlin A, Ferretti E, Falk M, Strapazzon G, Gamper M, Zanon P, Bock M, Rauch S. Lung Ultrasound and Respiratory Pathophysiology in Mechanically Ventilated COVID-19 Patients-an Observational Trial. *SN Compr Clin Med* 2020: 1-8 [PMID: 32995708 DOI: 10.1007/s42399-020-00536-1]

43 **Tung-Chen Y**, Martí de Gracia M, Parra-Gordo ML, Díez-Tascón A, Agudo-Fernández S, Ossaba-Vélez S. Usefulness of Lung Ultrasound Follow-up in Patients Who Have Recovered From Coronavirus Disease 2019. *J Ultrasound Med* 2020 [PMID: 33159704 DOI: 10.1002/jum.15556]

44 **Zhang Y**, Xue H, Wang M, He N, Lv Z, Cui L. Lung Ultrasound Findings in Patients With Coronavirus Disease (COVID-19). *AJR Am J Roentgenol* 2021; **216**: 80-84 [PMID: 32755198 DOI: 10.2214/AJR.20.23513]

45 **Tung-Chen Y**. Lung ultrasound in the monitoring of COVID-19 infection. *Clin Med (Lond)* 2020; **20**: e62-e65 [PMID: 32398268 DOI: 10.7861/clinmed.2020-0123]

46 **Hawkes RC**, Holland GN, Moore WS, Worthington BS. Nuclear magnetic resonance (NMR) tomography of the brain: a preliminary clinical assessment with demonstration of pathology. *J Comput Assist Tomogr* 1980; **4**: 577-586 [PMID: 6967878 DOI: 10.1097/00004728-198010000-00001]

47 **Smith FW**, Hutchison JM, Mallard JR, Johnson G, Redpath TW, Selbie RD, Reid A, Smith CC. Oesophageal carcinoma demonstrated by whole-body nuclear magnetic resonance imaging. *Br Med J (Clin Res Ed)* 1981; **282**: 510-512 [PMID: 6780102 DOI: 10.1136/bmj.282.6263.510]

48 **Grover VP**, Tognarelli JM, Crossey MM, Cox IJ, Taylor-Robinson SD, McPhail MJ. Magnetic Resonance Imaging: Principles and Techniques: Lessons for Clinicians. *J Clin Exp Hepatol* 2015; **5**: 246-255 [PMID: 26628842 DOI: 10.1016/j.jceh.2015.08.001]

49 **Huang L**, Zhao P, Tang D, Zhu T, Han R, Zhan C, Liu W, Zeng H, Tao Q, Xia L. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. *JACC Cardiovasc Imaging* 2020; **13**: 2330-2339 [PMID: 32763118 DOI: 10.1016/j.jcmg.2020.05.004]

**Footnotes**

**Conflict-of-interest statement:** The authors have nothing to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 28, 2021

**First decision:** May 6, 2021

**Article in press:**

**Specialty type:** Radiology, nuclear medicine and medical imaging

**Country/Territory of origin:** United Kingdom

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Liang XH, Tong MY **S-Editor:** Gao CC **L-Editor: P-Editor:**

**Table 1 Findings of thoracic imaging tools in coronavirus disease 2019 survivors**

|  |  |
| --- | --- |
| **Thoracic imaging tools** | **Imaging findings in COVID-19 survivors** |
| Chest X-ray (CXR) | (1) CRX does not correlate with abnormal CT findings or prolonged functional disability in infected patients; (2) Changes in CXR findings are associated with recovery duration and severity of COVID-19; and (3) The overall effectiveness of CRX is uncertain |
| CT scan | (1) Abnormal CT findings were detected in 71% of COVID-19 survivors; Unresolved lung tissue pathology presents mainly in the form of residual GGO; and (2) CT findings show a significant correlation with disease severity |
| Lung ultrasound (LUS) | (1) LUS findings correlate with chest CT and accurately assess the resolution of residual lung tissue abnormalities; and (2) LUS findings correlate with the duration of COVID-19 symptoms in COVID-19 survivors and can be used in home settings |
| MRI | (1) This is used to assess cardiac involvement in patients recovered from COVID-19; (2) 58% of recovered patients had abnormal MRI findings, including myocardial oedema (54%) and late gadolinium enhancement (31%); and (3) Fibrosis and compromised right ventricle function have also been found in patients who have recovered from COVID-19 |

COVID-19: Coronavirus disease 2019; CT: Computed tomography; MRI: Magnetic resonance imaging; GGO: Ground-glass opacity.